Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments.
暂无分享,去创建一个
[1] I. Katz,et al. Antidepressant studies in Parkinson's disease: A review and meta‐analysis , 2005, Movement disorders : official journal of the Movement Disorder Society.
[2] Zvi Israel,et al. Subthalamic stimulation for Parkinson's disease. , 2005, The Israel Medical Association journal : IMAJ.
[3] P. Pollak,et al. Symptomatic effect of selegiline in de novo parkinsonian patients , 1993, Movement disorders : official journal of the Movement Disorder Society.
[4] H. Checkoway,et al. Epidemiologic approaches to the study of Parkinson's disease etiology. , 1999, Epidemiology.
[5] L. Lynd,et al. Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders , 1998, The Annals of pharmacotherapy.
[6] N. Jaafari,et al. Stimulation cérébrale profonde, maladie de Parkinson et complications neuropsychiatriques , 2009 .
[7] H. Freund,et al. Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. , 2003, Archives of general psychiatry.
[8] C. Tanner,et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease , 1997, Neurology.
[9] M. Fava,et al. Pramipexole Augmentation in the Treatment of Unipolar and Bipolar Depression: A Retrospective Chart Review , 2000, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[10] C. Tanner,et al. Bupropion in Parkinson's disease , 1984, Neurology.
[11] J. H. Lee,et al. The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson’s disease , 2000, Journal of the Neurological Sciences.
[12] F. Girotti,et al. Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy , 1999, Journal of neurology, neurosurgery, and psychiatry.
[13] V. Chan‐Palay,et al. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression , 1989, The Journal of comparative neurology.
[14] T. Simuni,et al. Nonmotor manifestations of Parkinson's disease , 2008, Annals of neurology.
[15] Stephen M. Stahl,et al. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. , 2004, Primary care companion to the Journal of clinical psychiatry.
[16] C. Clarke,et al. Systematic review of antidepressant therapies in Parkinson's disease. , 2003, Parkinsonism & related disorders.
[17] R. Hauser,et al. Current issues in depression in Parkinson's disease. , 1999, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[18] M. Lemke,et al. Effect of reboxetine on depression in Parkinson's disease patients. , 2002, The Journal of clinical psychiatry.
[19] Dwight L. Evans,et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression , 2000, Depression and anxiety.
[20] M. Lemke. Dopamine agonists in the treatment of non‐motor symptoms of Parkinson’s disease: depression , 2008, European journal of neurology.
[21] J. Velíšková,et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study , 2003, European journal of neurology.
[22] H. Marín,et al. Treatment of depression in Parkinson’s disease , 2006, Current psychiatry reports.
[23] S. Buyske,et al. A controlled trial of antidepressants in patients with Parkinson disease and depression , 2009, Neurology.
[24] D. Burn. Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[25] A. Lieberman. Depression in Parkinson's disease – a review , 2006, Acta neurologica Scandinavica.
[26] A. Benabid,et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[27] H. Higuchi,et al. Remarkable effect of milnacipran, a serotonin–noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[28] K. Cook,et al. Prevalence and treatment of depression in Parkinson's disease. , 2005, The Journal of neuropsychiatry and clinical neurosciences.
[29] H. Grunze,et al. [The relevance of dopamine agonists in the treatment of depression]. , 2009, Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater.
[30] B. Alexander,et al. Retrospective Study of Selegiline–Antidepressant Drug Interactions and a Review of the Literature , 1997 .
[31] J. En,et al. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. , 1999 .
[32] S. Kapur,et al. A Dopaminergic Hypothesis of Major Depression , 1995 .
[33] J. Jefferson,et al. Psychiatric complications of deep brain stimulation for Parkinson's disease. , 2004, The Journal of clinical psychiatry.